Asuragen Pharmacogenomic Services has received a license from Roche Molecular Systems for clinical gene expression profiling and DNA analysis utilizing Roche's real-time quantitative PCR technology (qRT-PCR, qPCR). This agreement provides Asuragen access to intellectual property rights that broaden its clinical testing capabilities.
"As our bio-pharmaceutical clients move their testing out of discovery and into clinical research and trials, Asuragen is proud to be the first pharmacogenomic service provider to offer qRT-PCR assays for pharmaceutical drug trials," stated Scott Hunicke-Smith, General Manager of Asuragen Services.
With these newly acquired rights and Asuragen's recent CLIA registration, Asuragen’s robust microRNA and mRNA profiling services can be used to test predictive biomarker signatures, efficacy markers, and patient stratification tests during clinical and drug trials.
Asuragen Services offers a full range of clinical services including: assay design, development, and validation, FFPE and PAXgene® blood RNA isolation, and QC testing. Asuragen also conducts biomarker bridging studies from fresh to FFPE tissues and from array to qRT-PCR assay.